ğŸ§¬ GENE OF THE WEEK: OPRM1

The pain and reward receptor gene. OPRM1 variants affect pain sensitivity, opioid dosing requirements, and addiction vulnerability.

OPRM1 encodes the mu-opioid receptorâ€”the primary target of opioid pain medications and endogenous endorphins.

A118G Polymorphism:

A/A (Common):
âœ… Normal receptor function
âœ… Standard opioid response
âœ… Typical pain sensitivity
âœ… Standard naltrexone response
âœ… Baseline addiction risk

G Carriers (A/G, G/G):
âš ï¸ Reduced receptor binding
âš ï¸ Need higher opioid doses (30-50% more)
âš ï¸ Increased pain sensitivity
âš ï¸ Better naltrexone response
âš ï¸ Higher addiction risk
âš ï¸ Less natural endorphin effect

Clinical Implications:

Pain Management:
â†’ G carriers often require higher morphine/fentanyl doses
â†’ May appear "drug-seeking" when undertreated
â†’ Alternative pain strategies may be preferable

Addiction Treatment:
â†’ G carriers respond better to naltrexone (Vivitrol)
â†’ Important for medication-assisted treatment selection

Knowing your OPRM1 status helps personalize both pain management and addiction prevention strategies.

ğŸ‘¨â€âš•ï¸ Physicians: Why aren't you using Bioscope.AI to offer true AI-powered precision medicine?

ğŸ§‘ Patients: Why isn't your physician using Bioscope.AI to maximize your healthy longevity?

#GeneOfTheWeek #OPRM1 #Pain #Opioids #Pharmacogenomics #Bioscope
